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ABSTRACT Quantitative whole-body autoradiography was used to assess the distri-
bution and tissue penetration of isavuconazole in rats following single and repeated
oral-dose administration of radiolabeled isavuconazonium sulfate, the prodrug of isa-
vuconazole. Following a single-dose administration of radiolabeled isavuconazonium
sulfate (labeled on the active moiety), radioactivity was detectable within 1 h post-
dose in 56 of 65 tissue/ﬂuid specimens. The highest maximum concentrations (Cmax)
were observed in bile and liver (66.6 and 24.7 g eq/g, respectively). The lowest
Cmax values were in bone and eye lens (0.070 and 0.077 g eq/g, respectively). By
144 h postdose, radioactivity was undetectable in all tissues/ﬂuids except liver (un-
detectable at 336 h) and adrenal gland tissues (undetectable at 672 h). Following
daily administration for up to 21 days, 1-h-postdose Cmax values were the highest on or
before day 14 in all except seven tissues/ﬂuids, of which only rectum mucosa and small
intestine mucosa had Cmax values 25% higher than all other 1-h-postdose values. For
24-h-postdose Cmax values, only large intestine, large intestine mucosa, and urine had
the highest Cmax values at day 21. The penetration of single oral doses of unlabeled
isavuconazole (25 mg/kg of body weight isavuconazonium sulfate) and voriconazole
(50 mg/kg) into rat brain (assessed using liquid chromatography-tandem mass spec-
trometry) was also compared. Brain concentration/plasma concentration ratios reached
approximately 1.8:1 and 2:1, respectively. These data suggest that isavuconazole pene-
trates most tissues rapidly, reaches a steady state in most or all tissues/ﬂuids within
14 days, does not accumulate in tissues/ﬂuids over time, and achieves potentially ef-
ﬁcacious concentrations in the brain.
KEYWORDS isavuconazole, isavuconazonium sulfate, quantitative whole-body
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Invasive fungal infections (IFIs), such as invasive aspergillosis (IA), present a consid-erable therapeutic challenge, particularly among immunocompromised patient pop-
ulations, such as hematopoietic stem cell transplant recipients (1) or those with
hematological malignancies (2). The tissue penetration of a systemically administered
antifungal drug is a key aspect affecting efﬁcacy (3). The concentration-time course and
the absolute concentration obtained in tissues may be markedly different from those
obtained in the bloodstream (3, 4). Pharmacological factors (drug formulations, route of
administration), physiological factors (inﬂammation, underlying disease, the blood-brain
barrier), and lipophilicity are determinants of the penetration of drugs in tissues (3).
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Considerable variability in the relative distribution of antifungal agents in plasma and
various tissues has been observed. For example, ﬂuconazole concentrations in brain
tissue have been shown to be similar to those in plasma in a study in patients with
cerebral tumors (5), while the amphotericin B distribution in autopsy samples was
variable, with higher levels of accumulation in liver and spleen than brain (6). Caspo-
fungin also showed a variable distribution in the tissues of healthy men, with the
highest concentrations being reported in liver, kidney, lung, and spleen but little being
detected in the brain or the eye (7). In a study of human autopsy samples, voriconazole
effectively penetrated all subcompartments within the central nervous system (CNS) (8).
Isavuconazonium sulfate, the prodrug of the active triazole antifungal drug isavu-
conazole, is available in both oral and intravenous (i.v.) formulations. Following admin-
istration, isavuconazonium sulfate is rapidly cleaved to release the active isavuconazole
moiety and an inactive moiety, BAL8728 (9, 10). Isavuconazole has broad-spectrum
activity against molds, yeasts, and dimorphic fungi (11–13). In vivo antifungal activity
has been shown in animal models of invasive systemic and pulmonary aspergillosis
as well as mucormycosis (9, 14–19). In these murine models of disseminated fungal
infections, isavuconazole treatment reduced the fungal burden in the lung, liver,
kidney, and brain, suggesting that isavuconazole achieved effective concentrations at
these sites. Phase 3 studies in patients demonstrated the efﬁcacy and safety of
isavuconazole for the treatment of IA (20) and mucormycosis (21). As a result, isavu-
conazonium sulfate is approved by the Food and Drug Administration (FDA) for the
treatment of IA and mucormycosis in adults and by the European Medicines Agency for
the treatment of IA in adults and for the treatment of mucormycosis in adults when
amphotericin B is inappropriate.
Herein we report the results of studies conducted using radiolabeled isavuconazo-
nium sulfate to determine the tissue penetration and distribution of isavuconazole
drug-derived radioactivity in various tissues of rats following single or repeated oral-
dose administration in rats using quantitative whole-body autoradiography (QWBA). In
addition, the penetration of isavuconazole in rat brain was compared with that of
voriconazole following a single oral dose of either drug.
RESULTS
QWBA studies of 14C-labeled isavuconazonium sulfate in pigmented rats fol-
lowing single oral-dose administration. To assess the tissue penetration and distri-
bution of isavuconazole with single oral doses of isavuconazonium sulfate, rats were
given 14C-labeled isavuconazonium sulfate orally at 5 mg/kg of body weight, with
labeling being on the active moiety (Fig. 1), prior to sacriﬁce between 1 and 672 h later
(see Materials and Methods). Radioactivity was quantiﬁable in most tissues and ﬂuids by
1 h postdose and reached a maximum within 2 h postdose in blood, other ﬂuids, and
most tissues except the eye lens and fat tissues (mesenteric, reproductive, and white
fat; all at 8 h) (Table 1). At assessment times of 24 h postdose, most tissue concen-
trations exceeded those in blood, indicating partitioning of drug-derived radioactivity
into most tissues. High levels of radioactivity were found in the kidneys and the uveal
tract up to 8 h postdose, and tissue concentration/blood concentration ratios fre-
quently exceeded 2:1 (Fig. 2A). The highest maximum concentration (Cmax) values were
FIG 1 Structure of [cyano-14C]isavuconazonium sulfate. Red, isavuconazole; black, inactive prodrug
moiety (BAL8728); 14C, the position of the radiolabel.
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TABLE 1 Concentrations of radioactivity in tissues and ﬂuids determined by QWBA at speciﬁed times after single oral-dose administration
of [cyano-14C]isavuconazonium sulfate in male pigmented ratsc
Matrix
Concn of [cyano-14C]isavuconazonium sulfate (g eq/g) at:
1 h 2 h 4 h 8 h 24 h 72 h 144 h 336 h 672 h
Adrenal cortex 5.76a 11.0a 7.14 7.91 2.46 1.03 0.348 0.169 BLQa
Adrenal gland(s) 5.05a 10.6a 6.99 7.50 2.31 0.908 0.270 0.136 BLQa
Adrenal medulla 2.58a 4.44a 5.05 4.01 1.32 0.317 0.085 0.047 BLQa
Aorta 0.640 1.14 0.339 0.427 ND ND ND ND ND
Arterial wall 0.645 0.923 0.348 0.465 ND ND ND ND ND
Bile 147 66.6 21.6 19.0 ND ND ND ND ND
Blood 0.463 0.603 0.252 0.247 0.092 BLQ ND ND ND
Bone 0.048 0.070 BLQ BLQ BLQ ND ND ND ND
Bone marrow 0.717 0.822 0.287 0.279 0.054 ND ND ND ND
Brain cerebellum 0.597 0.887 0.234 0.322 BLQ ND ND ND ND
Brain cerebrum 0.533 0.808 0.216 0.272 BLQ ND ND ND ND
Brain medulla 0.641 0.912 0.249 0.321 BLQ ND ND ND ND
Brain olfactory lobe 0.485 0.591 0.189 0.234 BLQ ND ND ND ND
Bulbourethral gland 0.846 1.54 0.543 0.534 0.094 ND ND ND ND
Cecum 1.47 0.725 0.696 0.625 0.448 ND ND ND ND
Cecum mucosa 1.33 1.01 1.01 0.916 0.512 ND ND ND ND
Diaphragm 0.879 1.25 0.385 0.501 0.079 ND ND ND ND
Epididymis 0.556 1.42a 0.754 0.577 0.116 BLQ ND ND ND
Esophagus 0.721 0.974 0.346 0.382 0.081 BLQ ND ND ND
Exorbital lacrimal gland 1.35 1.94 0.675 0.698 0.106 BLQ ND ND ND
Eye lens BLQ 0.050 BLQ 0.077 0.060 ND ND ND ND
Eye uveal tract 1.02 1.59 1.04 1.15 0.374 0.097 ND ND ND
Eye(s) 0.180 0.312 0.200 0.191 0.084 BLQ ND ND ND
Fat (brown) 1.27 3.76 1.35 1.26 0.142 BLQ ND ND ND
Fat (mesenteric) 0.784 2.34 2.68 3.24 0.287 BLQ ND ND ND
Fat (reproductive) 0.557 1.84 2.11 2.79 0.747 BLQ ND ND ND
Fat (white) 1.04 2.47 2.50 2.84 0.275 BLQ ND ND ND
Harderian gland 1.66 3.74 1.13 1.11 0.165 ND ND ND ND
Intra-orbital lacrimal gland 1.27 1.91 0.675 0.675 0.129 ND ND ND ND
Kidney cortex 2.04 2.77 1.14 1.12 0.176 BLQ ND ND ND
Kidney medulla 2.40 3.29 1.21 0.998 0.159 BLQ ND ND ND
Kidney(s) 2.29 3.04 1.19 1.06 0.170 BLQ ND ND ND
Large intestine 0.789 1.05 0.402 0.650 0.206 BLQ ND ND ND
Large intestine mucosa 0.879 1.11 0.470 0.781 0.312 BLQ ND ND ND
Liver 24.7 15.7 6.21 5.31 1.45 0.392 0.138 BLQ ND
Lung(s) 0.743 0.915 0.292 0.381 0.082 BLQ ND ND ND
Lymph node(s) 0.529 0.651 0.289 0.300 0.054 ND ND ND ND
Lymph node(s), mandibular 0.577 0.730 0.263 0.317 0.048 ND ND ND ND
Muscle 0.530 0.812 0.255 0.278 BLQ BLQ ND ND ND
Myocardium 1.03 1.47 0.489 0.589 0.080 BLQ ND ND ND
Nasal mucosa 0.589 1.38 0.467 0.436 0.124 0.042 ND ND ND
Pancreas 1.49 1.60 0.676 0.769 0.080 BLQ ND ND ND
Pineal body NR 1.13 0.345 0.490 ND ND ND ND ND
Pituitary gland 0.811 1.25 0.431 0.535 0.084 ND ND ND ND
Preputial gland 0.576a 1.47a 0.900a 1.28a 0.202a 0.073 ND ND ND
Prostate gland 0.975 1.71 0.608 0.572 0.069 BLQ ND ND ND
Rectum mucosa 0.581 1.04 0.207 0.513 0.221 BLQ ND ND ND
Salivary gland(s) 1.12 1.52 0.485 0.531 0.070 ND ND ND ND
Seminal vesicle(s) 0.157 0.341 0.194 0.163 0.059 BLQ ND ND ND
Skin (nonpigmented) 0.378 0.872 0.325 0.321 0.080 BLQ ND ND ND
Skin (pigmented) 0.520 0.910 0.511 0.461 0.121 0.052 ND ND ND
Small intestine 1.50 1.72 1.07 0.970 0.259 ND ND ND ND
Small intestine mucosa 2.52 2.18 1.78 1.45 0.553 ND ND ND ND
Spinal cord 0.595 0.948 0.284 0.315 BLQ ND ND ND ND
Spleen 0.763 0.850 0.306 0.380 0.093 BLQ ND ND ND
Stomach 1.21 1.77 0.540 0.513 0.093 0.077 ND ND ND
Stomach mucosa 2.22 2.43 0.891 0.614 0.104 0.103 ND ND ND
Stomach wall 0.946 1.01 0.356 0.362 0.086 BLQ ND ND ND
Testis(es) 0.507 1.03 0.520 0.512 0.146 0.070 ND ND ND
Thymus 0.543 0.827 0.259 0.287 0.072 ND ND ND ND
Thyroid 0.858 1.09 0.389 0.447 0.104 ND ND ND ND
Tongue 0.954 1.17 0.428 0.422 0.049 ND ND ND ND
Tooth pulp 0.592 0.628 0.261 0.216 0.048 ND ND ND ND
Urinary bladder NDb 1.63a 0.535 0.406 ND ND ND ND ND
Urine 17.5 54.7 8.61 8.95 2.90 0.195 ND ND ND
aThe tissue appeared to be fat soaked.
bThe urinary bladder could not be sampled due to the ﬂare from the urine.
c[cyano-14C]isavuconazonium sulfate was administered at 5 mg/kg. The correction factor of 1.1352 (sulfate/free form) was applied to calculate the concentrations of
free base equivalents of radioactivity in tissues, bile, blood, and urine. BLQ, below the limit of quantitation (0.0414 g equivalents [cyano-14C]isavuconazonium
sulfate/g); ND, not detectable (the borders of the sample were indiscernible from the background or surrounding tissue); NR, not represented (tissue was not present
in the section); QWBA, quantitative whole-body autoradiography.
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observed in bile, liver, adrenal gland, adrenal cortex, and brown fat (66.6 [2 h postdose],
24.7 [1 h postdose], 10.6 [2 h postdose], 11.0 [2 h postdose], and 3.76 [2 h postdose] g
eq/g, respectively). The lowest Cmax values were in bone, eye lens, eye, seminal vesicles,
olfactory bulb, and blood (0.070, 0.077, 0.312, 0.341, 0.591, and 0.603 g eq/g, respec-
tively). By 72 h postdose, the amount of radioactivity in blood and all tissues and ﬂuids
declined below measurable levels, except as follows: nasal mucosa, preputial gland,
pigmented skin, stomach, stomach mucosa, testis, urine, and uveal tract (all undetect-
able by 144 h); liver (undetectable by 336 h); and adrenal glands, including the cortex
and medulla (undetectable by 672 h). The concentrations of drug-derived radioactivity
were similar and decreased with the same pattern in pigmented and nonpigmented
skin, indicating no additional afﬁnity for melanin.
The amount of radioactivity in whole blood and plasma measured by liquid scintil-
lation counting (LSC) was consistent with that measured by QWBA. The Cmax for both
blood and plasma radioactivity occurred at 2 h postdose at 0.603 and 0.891 g eq/g,
respectively, resulting in a ratio of 0.620 at the time of Cmax (Tmax). Blood concentration/
plasma concentration ratios were 0.620 to 0.782 through 24 h postdose but increased
to 1.06 and 2.38 at 72 h and 144 h, respectively, indicating either a slow redistribution
from plasma to blood cells through 24 h or a slower clearance from blood cells than
plasma at later times. The elimination half-lives in blood and plasma were 340 h and
28.1 h, respectively. The area under the concentration-time curve from time zero to
inﬁnity (AUCinf) for blood and plasma were 17.3 g eq · h/ml and 13.4 g eq · h/ml,
respectively.
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FIG 2 Tissue concentration/blood concentration ratios of 14C radioactivity determined by quantitative
whole-body autoradiography (QWBA) at speciﬁed time points after single oral administration (A) or
repeated oral administration (B) of [cyano-14C]isavuconazonium sulfate to male rats.
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QWBA study of 14C-labeled isavuconazonium sulfate in albino rats following
repeated oral-dose administration. To assess the distribution and potential accumu-
lation of isavuconazole following repeated oral doses of isavuconazonium sulfate, rats
were given 14C-labeled isavuconazonium sulfate at 30 mg/kg daily for up to 21 days
and sacriﬁced at times between 1 h and 672 h postdose (see Materials and Methods).
In 31 of 62 tissue and ﬂuid specimens for which 1-h-postdose samples on day 1 were
available for comparison, the concentrations of radioactivity were similar (2-fold increase)
at 1 h postdose on days 7, 14, and 21 (Tables 2 and 3). Among the tissues and ﬂuids for
which2-fold increases for Cmax values were seen in 1-h-postdose samples subsequent to
day 1, Cmax was observed on day 7 in 4 tissues and ﬂuids (bile, reproductive fat, seminal
vesicles, and stomach wall), on day 14 in 20 tissues and ﬂuids (adrenal tissues [adrenal
gland, cortex, medulla], intestinal tissues [cecum, cecum mucosa, large intestine, large
intestine mucosa], reproductive tissues [bulbourethral gland, epididymis, testes], lymph
tissues [lymph nodes, mandibular lymph nodes], aorta, blood, intraorbital lacrimal
gland, kidney medulla, nasal mucosa, spinal cord, tooth pulp, and urine), and on day 21
in 7 tissues and ﬂuids (intestinal tissues [rectum mucosa, small intestine, small intestine
mucosa], mesenteric fat, pineal body, nonpigmented skin, and thyroid). Among tissues
and ﬂuids with a 1-h-postdose Cmax on day 21, only two tissues, rectum mucosa and
small intestine mucosa, had concentrations that were 25% higher than those at 1 h
postdose on any previous assessment day. These higher levels were possibly due to
contamination by residual intestinal contents. These data suggest that steady-state
concentrations were achieved in most or all tissues and ﬂuids on or before day 14.
In 24-h-postdose samples from days 1, 7, 14, and 21, radioactivity was frequently
undetectable (Tables 2 and 3). Among 27 tissues and ﬂuids for which day 1 samples
were available for comparison, 2-fold increases were observed at any subsequent
assessment day in 17 tissues. Tissues with the highest 24-h-postdose Cmax on day 14
included adrenal tissues (adrenal glands, adrenal cortex), cecum mucosa, brown fat,
liver, and urinary bladder. The tissues and ﬂuids with the highest 24-h-postdose Cmax on
day 21 included large intestine tissues (large intestine, large intestine mucosa) and
urine. These data suggest that there was no substantial accumulation of isavuconazole
in any tissues.
The tissue/ﬂuid distribution patterns and the elimination of radioactivity from most
tissues and ﬂuids in albino rats that received repeated oral-dose administration of
radiolabeled isavuconazonium sulfate were largely similar through the 24-h-postdose
observation period to those in the same strain of rats administered a single dose of
radiolabeled isavuconazonium sulfate. Adrenal gland tissues and the liver consistently
had among the highest Cmax values at all time points, whereas bone, eye lens, and eye
consistently had among the lowest Cmax values at all time points. In LSC analyses, day
21 blood and plasma elimination half-lives were 319 and 48.2 h, respectively. The blood
and plasma AUCinf values on day 1 were 67.6 and 105 g eq · h/ml, respectively. The
elimination half-life of each tissue on day 1 could not be calculated because the
sampling time on day 1 was limited to 24 h. The AUCinf values of the free base
equivalents of total radioactivity were 4-fold higher for blood than plasma (550 and
135 g eq · h/ml, respectively) after 21 consecutive daily doses.
Similar to the incremental increase in the concentration of drug-derived radioactiv-
ity in tissues between days 1 and 14, the concentration of drug-derived radioactivity in
blood also increased upon repeated administration. The radioactivity increased more
markedly in blood than in tissues, so that overall the tissue concentration/blood
concentration ratios decreased between days 1 and 14. The tissue concentration/blood
concentration ratios at 1 h postdose on days 1, 7, and 14 and 24 h postdose on day 14
were examined for the same tissues assessed in the single-dose study (Fig. 2B). Similar
to the observation for single-dose administration, the highest ratios were observed for
kidney, which were 2:1 at the 1-h-postdose time points on each assessment day. The
ratios for all tissues decreased decrementally in 1-h-postdose samples from days 7 and
14, reﬂecting the greater incremental increases in the blood concentrations at those
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TABLE 2 Concentrations of radioactivity in tissues and ﬂuids determined by QWBA at speciﬁed times after oral administration of
[cyano-14C]isavuconazonium sulfate for up to 21 consecutive days in male albino ratsb
Matrix
Concn of [cyano-14C]isavuconazonium sulfate (g eq/g) at the indicated times after the last dose on:
Day 1 Day 7 Day 14
1 h 4 h 8 h 24 h 1 h 24 h 1 h 24 h
Adrenal cortex 10.1a 24.1a 19.0a 6.54a 20.9a 14.3a 23.1a 16.9a
Adrenal gland(s) 9.51a 22.7a 17.1a 5.83a 19.3a 12.4a 21.2a 14.0a
Adrenal medulla 8.04a 17.9a 10.8a 3.47a 11.7a 6.37a 19.2a 5.12a
Aorta 2.00 4.67 3.76 ND 2.75 1.51 4.53 2.35
Arterial wall ND 5.53 ND ND 1.88 ND 3.43 ND
Bile 101 198 109 27.3 472 27.7 157 ND
Blood 0.783 1.99 1.81 ND 1.70 1.34 3.04 1.41
Bone BLQ BLQ BLQ ND BLQ BLQ BLQ BLQ
Bone marrow 2.35 4.23 3.41 ND 1.90 0.979 4.03 BLQ
Brain cerebellum 1.55 3.28 2.11 ND 1.81 BLQ 2.74 BLQ
Brain cerebrum 1.51 3.36 2.02 ND 1.86 BLQ 2.72 BLQ
Brain medulla 1.60 3.52 2.22 ND 1.79 BLQ 2.93 BLQ
Brain olfactory lobe 1.46 2.93 1.70 ND 1.44 BLQ 2.46 BLQ
Bulbourethral gland 2.21 6.14 4.67 ND 3.08 0.933 4.60 1.27
Cecum BLQ 12.9 9.22 7.13 6.41 6.57 13.5 13.6
Cecum mucosa 4.12 15.8 13.7 7.42 16.6 11.4 18.2 10.9
Diaphragm 2.86 5.22 3.97 BLQ 3.52 0.920 5.01 1.27
Epididymis 1.00a 4.88 3.07 ND 1.57 0.819a 2.26a 0.925a
Esophagus 3.00 4.44 2.51 0.896 2.10 1.19 2.89 BLQ
Exorbital lacrimal gland 3.62 9.17 7.04 0.881 3.94 1.37 6.64 1.21
Eye lens BLQ BLQ BLQ ND BLQ BLQ BLQ BLQ
Eye uveal tract 1.21 2.40 1.31 ND 1.39 1.06 2.16 0.948
Eye(s) BLQ BLQ BLQ ND BLQ BLQ 0.787 BLQ
Fat (brown) 5.34 8.80 8.56 0.939 7.00 1.69 9.92 2.20
Fat (mesenteric) 0.802 23.4 21.0 1.80 2.96 2.21 1.17 2.67
Fat (reproductive) BLQ 16.0 15.5 2.27 3.76 3.66 2.03 3.73
Fat (white) 1.74 26.7 16.8 1.59 2.53 2.20 2.39 1.42
Harderian gland 3.63 12.6 9.14 1.03 4.55 1.73 6.58 1.38
Intra-orbital lacrimal gland 3.34 7.94 6.51 ND 3.38 1.39 6.77 1.33
Kidney cortex 4.67 10.4 6.96 ND 6.60 2.42 9.24 2.73
Kidney medulla 4.64 9.76 6.43 ND 6.10 2.43 9.31 2.33
Kidney(s) 4.65 10.2 6.80 1.42 6.46 2.43 9.29 2.58
Large intestine BLQ 3.25 4.05 1.91 3.49 1.90 4.00 1.46
Large intestine mucosa 2.55 4.80 2.88 1.92 3.21 4.06 5.32 2.31
Liver 35.8 38.3 31.5 7.53 40.1 15.6 58.8 18.4
Lung(s) 2.03 4.61 3.49 0.757 3.13 1.41 3.14 1.16
Lymph node(s) 1.22 3.57 3.02 ND 2.06 0.987 2.80 1.12
Lymph node(s), mandibular 1.35 3.61 2.78 ND 1.82 ND 2.96 ND
Muscle 1.32 3.64 2.43 BLQ 1.59 BLQ 1.84 BLQ
Myocardium 3.10 6.79 4.32 0.964 3.99 1.49 5.60 1.83
Nasal mucosa 1.36 6.08 3.64 0.895 1.98 1.19 3.17 1.76
Pancreas 3.99 8.09 5.77 0.749 4.20 1.05 6.34 1.17
Pineal body 1.84 5.31 3.93 ND 4.13 ND 4.47 ND
Pituitary gland 2.50 4.61 2.80 ND ND ND 4.85 ND
Preputial gland ND 8.32a 12.0a ND 4.00a 3.12a 4.52a 2.20a
Prostate gland 2.78 13.0 5.39 BLQ 3.24 1.10 3.23 1.17
Rectum mucosa 0.989 2.61 2.00 0.821 1.75 0.778 1.55 1.30
Salivary gland(s) 2.91 5.91 4.29 BLQ 3.56 0.868 5.03 0.941
Seminal vesicle(s) BLQ 3.32 1.62 BLQ 1.97 0.783 1.63 0.938
Skin (nonpigmented) 1.06 3.64 3.33 BLQ 1.87 0.988 2.16 1.01
Small intestine 1.74 4.50 12.9 3.65 9.95 3.07 10.0 2.57
Small intestine mucosa 3.15 14.6 21.7 7.81 16.7 7.26 21.9 9.43
Spinal cord 1.41 3.74 2.16 ND 1.80 ND 2.92 BLQ
Spleen 2.12 3.68 3.28 ND 2.47 1.00 4.02 1.11
Stomach 4.31 5.10 4.41 BLQ 4.74 1.56 5.93 1.11
Stomach mucosa 5.48 7.97 6.16 ND 6.27 ND 9.00 ND
Stomach wall 1.57 2.61 1.98 ND 3.19 ND 2.43 ND
Testis(es) 1.01 3.21 2.28 BLQ 1.50 0.882 2.26 1.00
Thymus 1.42 2.86 2.03 BLQ 1.53 BLQ 2.26 BLQ
Thyroid 2.15 5.39 3.76 ND 4.88 2.08 5.23 2.52
Tongue 2.43 5.70 3.59 BLQ 3.22 0.927 4.27 0.970
Tooth pulp 1.23 2.50 1.71 ND 1.67 1.07 3.07 0.884
Urinary bladder 5.39 9.97 3.69 3.77 4.79 1.71 2.67 12.8
Urine 8.85 119 102 9.75 16.6 16.4 58.0 20.4
aTissue appeared to be fat soaked.
b[cyano-14C]isavuconazonium sulfate was administered at 30 mg/kg/day. BLQ, below the limit of quantitation (the lower limit of quantitation for day 1 was 0.742 g
eq [cyano-14C]isavuconazonium sulfate/g; the lower limit of quantitation for days 7 and 14 was 0.748 g eq [cyano-14C]isavuconazonium sulfate/g); ND, not
detectable (the borders of the sample were not discernible from the background or surrounding tissue); QWBA, quantitative whole-body autoradiography.
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TABLE 3 Concentrations of radioactivity in tissues and ﬂuids determined by QWBA at speciﬁed times after oral administration of
[cyano-14C]isavuconazonium sulfate for 21 consecutive days in male albino ratse
Matrix
Concn of [cyano-14C]isavuconazonium sulfate (g eq/g) at:
Predosea 1 ha 4 ha 8 ha 24 ha 72 ha,b 168 ha 336 ha 672 ha
Adrenal cortex 17.2c 22.8c 33.6c 26.4c 12.7c 10.4 4.45c 2.43c 1.29
Adrenal gland(s) 14.3c 20.7c 29.2c 22.4c 11.4c 7.78 3.81c 2.14c 1.13
Adrenal medulla 6.86c 8.12c 13.3c 10.5c 7.21c 3.41 1.94c 1.02c BLQ
Aorta 1.20 4.22 6.37 3.44 ND ND ND ND ND
Arterial wall ND ND 6.91 3.12 ND ND ND ND ND
Bile 37.6 186 231 194 25.3 ND ND ND ND
Blood 1.21 2.60 3.73 2.18 1.01 BLQ BLQ BLQ ND
Bone BLQ BLQ BLQ BLQ BLQ ND ND ND ND
Bone marrow 0.975 3.24 7.10 2.34 BLQ ND ND ND ND
Brain cerebellum BLQ 2.59 5.15 1.70 BLQ ND ND ND ND
Brain cerebrum BLQ 2.66 5.45 1.68 BLQ ND ND ND ND
Brain medulla 0.813 2.79 5.45 1.88 BLQ ND ND ND ND
Brain olfactory lobe BLQ 2.34 4.52 1.69 BLQ ND ND ND ND
Bulbourethral gland 1.24 4.27 6.78 3.36 0.788 ND ND ND ND
Cecum 8.39 9.97 24.0 21.2 ND 1.08 BLQ ND ND
Cecum mucosa 20.1 16.6 43.7 40.5 ND ND ND ND ND
Diaphragm 1.13 3.84 7.51 3.09 0.753 0.764 BLQ ND ND
Epididymis 0.998c 2.22 5.93c 3.09c BLQc BLQ BLQ ND ND
Esophagus 0.928 2.52 4.29 2.59 BLQ BLQ ND ND ND
Exorbital lacrimal gland 1.26 5.60 11.2 5.04 1.20 BLQ BLQ BLQ ND
Eye lens BLQ 0.794 1.35 0.830 BLQ ND ND ND ND
Eye uveal tract BLQ 2.22 4.58 2.20 1.17 ND ND ND ND
Eye(s) BLQ BLQ 1.28 0.775 BLQ ND ND ND ND
Fat (brown) 2.30 9.33 17.7 8.62 1.50 1.19 1.11 BLQ ND
Fat (mesenteric) 1.46 3.43 18.7 7.62 2.33 0.781 BLQ ND ND
Fat (reproductive) 3.59 3.62 10.9 8.01 2.99 BLQ BLQ BLQ ND
Fat (white) 1.46 2.75 12.1 7.97 1.04 0.830 BLQ ND ND
Harderian gland 1.50 6.58 18.9 7.23 1.06 ND ND ND ND
Intra-orbital lacrimal gland 1.39 5.89 11.0 5.36 1.32 ND ND ND ND
Kidney cortex 2.64 8.76 16.1 7.53 2.33 1.64 1.05 0.969 BLQ
Kidney medulla 2.69 8.49 12.3 7.02 1.97 1.29 BLQ BLQ BLQ
Kidney(s) 2.64 8.59 13.7 7.33 2.16 1.52 0.871 0.885 BLQ
Large intestine 6.87 3.65 6.41 4.44 1.92 BLQ BLQ ND ND
Large intestine mucosa NDd 4.37 9.18 4.99 5.15 ND ND ND ND
Liver 14.6 54.4 64.4 41.4 14.2 7.80 2.95 1.09 BLQ
Lung(s) 0.957 3.38 6.34 3.70 0.814 BLQ BLQ ND ND
Lymph node(s) BLQ 2.44 5.54 2.70 ND ND ND ND ND
Lymph node(s), mandibular BLQ 2.87 5.33 2.73 ND ND ND ND ND
Muscle BLQ 1.27 4.38 1.71 BLQ BLQ ND BLQ ND
Myocardium 1.92 5.77 10.7 4.41 1.47 1.36 0.901 0.777 ND
Nasal mucosa 1.87 3.04 6.38 4.03 0.931 0.834 ND ND ND
Pancreas 1.05 5.91 10.5 4.10 BLQ BLQ BLQ BLQ ND
Pineal body ND 5.49 9.42 3.94 ND ND ND ND ND
Pituitary gland ND 2.88 7.46 2.97 ND ND ND ND ND
Preputial gland 2.29c 4.85c 10.8c 6.68c 4.65c 2.02 1.42 ND ND
Prostate gland 0.998 4.33 13.9 3.66 0.839 BLQ BLQ ND ND
Rectum mucosa 0.886 4.54 4.57 4.63 BLQ ND ND ND ND
Salivary gland(s) 1.40 4.52 9.15 3.36 BLQ BLQ BLQ ND ND
Seminal vesicle(s) BLQ 1.92c 2.89 1.64 BLQ BLQ BLQ ND ND
Skin (nonpigmented) 1.01 2.25 3.85 2.68 BLQ BLQ BLQ BLQ ND
Small intestine 4.59 12.1 18.9 11.3 2.38 ND ND ND ND
Small intestine mucosa 7.89 32.5 39.6 26.9 13.6 ND ND ND ND
Spinal cord BLQ 2.68 5.84 1.76 ND ND ND ND ND
Spleen 1.40 3.50 6.76 3.17 1.09 0.830 BLQ BLQ BLQ
Stomach 1.58 3.61 7.41 3.93 1.14 ND ND BLQ ND
Stomach mucosa ND 7.38 14.0 4.65 ND ND ND ND ND
Stomach wall ND 2.27 3.88 2.13 ND ND ND ND ND
Testis(es) 0.925 2.21 5.03 2.15 0.752 BLQ BLQ BLQ ND
Thymus BLQ 2.43 4.64 1.90 BLQ BLQ BLQ BLQ ND
Thyroid 2.09 5.74 10.6 4.05 3.23 2.20 2.78 1.56 ND
Tongue 1.15 4.04 8.00 3.10 0.809 ND ND ND ND
Tooth pulp 1.23 2.79 4.30 3.48 ND ND ND ND ND
Urinary bladder 1.09 3.60 NDd 19.0 ND ND ND ND ND
Urine 9.28 21.5 148 67.9 24.0 1.58 BLQ ND ND
aThe last dose that these animals received was on day 21.
bThe actual collection time point was 73.4 h postdose, as the sample was collected approximately 88 min after the scheduled collection time (approximately 28 min
outside of the acceptable standard range).
cThe tissue appeared to be fat soaked.
dNot detectable due to ﬂare from gastrointestinal contents (large intestine mucosa) or urine (urinary bladder).
e[cyano-14C]isavuconazonium sulfate was administered at 30 mg/kg/day. Dose times are relative to the day 21 dose. BLQ, below the limit of quantitation (the lower
limit of quantitation for day 21 was 0.748 g eq [cyano-14C]isavuconazonium sulfate/g); ND, not detectable (the sample shape was not discernible from the
background or surrounding tissue); QWBA, quantitative whole-body autoradiography.
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time points. By 24 h postdose on day 14, isavuconazole-associated radioactivity was
undetectable in the brain (Fig. 2B).
Oral dosing of unlabeled isavuconazonium sulfate in rats: brain and plasma
levels of isavuconazonium, isavuconazole, and voriconazole. To further character-
ize the penetration of isavuconazole in brain and compare it with that of voriconazole,
rats were administered a single oral dose of isavuconazole (25 mg/kg) or voriconazole
(50 mg/kg), and the concentrations of each drug in brain and plasma samples taken up
to 24 h later were assessed (see Materials and Methods). Following an oral dose, the
plasma concentration of isavuconazole reached a maximum within 3 h and then
declined biphasically (Fig. 3A; Table 4). Isavuconazole concentrations in brain declined
in parallel with those in plasma (Fig. 3B; Table 4). The brain concentrations of isavu-
conazole were approximately twice as high as the plasma concentrations, with an
overall mean brain AUC/plasma AUC ratio and mean individual brain AUC/plasma AUC
ratios of 1.8:1 (Table 4 and data not shown). The isavuconazonium prodrug was not
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FIG 3 Mean concentrations  standard deviations of isavuconazole (A, B) and voriconazole (C, D) in rats (n  3 at each time
point) following a single oral dose of 25 mg/kg isavuconazole (administered as isavuconazonium sulfate) or voriconazole. (A,
C) Log-linear scale; (B, D) linear-linear scale (note the differences in the y axis scales).
TABLE 4 Values of pharmacokinetic parameters for isavuconazole and voriconazole in
plasma and brain following a single oral administration in ratsa
Compound and
matrix t1/2 (h) Tmax (h)
Cmax
(g/ml)
AUClast
(g · h/ml) tlast (h)
AUCinf
(g · h/ml)
Isavuconazole
Brain 3.7 3.0 6.95 53.7 24 54.3
Plasma 3.8 3.0 3.67 30.3 24 30.7
Voriconazole
Brain ND 3.0 48.07 321.5 8 ND
Plasma 2.1 1.0 21.97 304.5 24 304.7
aAUCinf, area under the concentration-time curve from time zero to inﬁnity; AUClast, area under the
concentration-time curve from time zero to the last measurable time point; Cmax, maximum concentration
observed; ND, not determined; t1/2, half-life; tlast, last measurable time point; Tmax, time of maximum
concentration observed.
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detectable in plasma or brain (data not shown). The plasma concentrations of vori-
conazole following an oral dose were more variable, as no clear maximum was
observed within 8 h, although as also observed for isavuconazole, the concentrations
in brain declined in parallel with those in plasma (Fig. 3C and D). The measurable levels
of voriconazole in brain were approximately twice as high as those in plasma (average
of the individual brain concentration/plasma concentration ratios, 2:1; data not shown).
DISCUSSION
These studies characterized the penetration, distribution, and elimination of isavucona-
zole with oral dosing of the prodrug isavuconazonium sulfate in rats. Following a single oral
dose of radiolabeled prodrug, the maximum concentrations of isavuconazole-associated
radioactivity were reached by 2 h in most tissues and ﬂuids and by 8 h in all tissues and
ﬂuids. Radioactivity was undetectable after 144 h in almost all tissues except liver (from
which drug was eliminated at 336 h) and adrenal gland tissues (from which drug was
eliminated at 672 h). With repeated dosing for up to 21 days, steady-state concentra-
tions appeared to be reached by day 14 without strong evidence of accumulation in
any tissues. The only tissues or ﬂuids in which substantial increases in 1-h-postdose or
24-h-postdose concentrations were observed after day 14 were intestinal tissues and
urine, which might be expected to demonstrate some variability due to potential
contamination attributable to oral dosing (intestinal tissues) or variations in the excre-
tion of isavuconazole metabolites (urine). There were no clear differences between
radiolabel concentrations in the pigmented and nonpigmented skin, indicating that
isavuconazole was unlikely to bind to melanin. Following the administration of single
oral doses of unlabeled isavuconazonium sulfate, the brain penetration of isavucona-
zole was comparable to that of voriconazole, with the concentrations in brain being
approximately twice as high as those in plasma. Taken together, these studies suggest
that isavuconazole is potentially useful for the treatment of infections with susceptible
pathogens in a wide range of tissues, including the CNS.
These observations are consistent with the physicochemical properties of isavu-
conazole, which include a low molecular weight, a small polar surface area, interme-
diate lipophilicity, and high permeability (22) and the fact that it is not a substrate for
efﬂux transporters (23). They also provide a basis for the efﬁcacy of isavuconazole seen
in models in earlier preclinical studies. For example, in a murine model of disseminated
Aspergillus ﬂavus infection using isavuconazole treatment at 24 h postinfection, the
clearance of the organism from all organs (lung, liver, kidneys, and brain) was achieved
at 14 days postinfection in 5/6, 3/6, and 3/4 survivors receiving 30, 15, and 6 mg/kg
dose of the prodrug, respectively (9). The efﬁcacy of isavuconazole for clearance of the
tissue burden has been shown not to be speciﬁc to aspergillosis, as isavuconazole
demonstrated a signiﬁcant reduction in the fungal brain burden at all doses tested in
a murine model of disseminated Candida krusei infection (17). The relevance of these
data from preclinical studies for clinical efﬁcacy is also supported by the efﬁcacy of
isavuconazole observed in patients with disseminated fungal infections included in the
SECURE and VITAL trials (20, 21, 24).
It is well established that the limited brain penetration of many antifungal agents
limits their usefulness for the treatment of CNS infections (3). Although voriconazole is
not the only agent with efﬁcacy for the treatment of aspergillosis, it has become the
standard treatment for CNS aspergillosis because of both its efﬁcacy and its penetration
of brain (25, 26). The efﬁcacy of isavuconazole for the treatment of IA has been shown
to be comparable to that of voriconazole (20), but the extent of its penetration of the
CNS had not previously been assessed. Because isavuconazole is not a substrate for
efﬂux mediated by P-glycoprotein in humans (23), there was reason to believe that
isavuconazole might also reach potentially therapeutic concentrations in the brain. As
pointed out by others (27), studies of the CNS penetration of other agents have
frequently relied on the concentrations observed in cerebrospinal ﬂuid, which may not
accurately reﬂect penetration into tissues. The current study assessed the concentra-
tions in brain tissues directly and observed a 1.8:1 brain concentration/plasma concen-
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tration ratio for isavuconazole, similar to that observed for voriconazole (2:1) and to the
value reported previously by others for voriconazole in rats (1.88:1) (27). Given that a
previous study of voriconazole also found evidence of concentrations in human brain
at least 2-fold higher than those in plasma (27), it seems likely that the similarity of the
data for both agents in rats will extend to humans as well. The potential utility of
isavuconazole for CNS infections is supported by case reports of successful treatment
of such infections (28–30). On the other hand, it is unclear whether the much more
limited penetration of bone by isavuconazole in rats can be extrapolated to humans
and might limit its efﬁcacy to treat those infections.
In addition to any uncertainty over the extent to which the results can be extrap-
olated to humans, this study has other important limitations. As is the standard practice
for QWBA studies, only one animal was assessed per time point, so estimates of
interanimal variability could not be determined. For the studies with radiolabeled
isavuconazonium sulfate, we could not determine the contribution of the by-products
of isavuconazole metabolism to the radioactivity in any tissues. Indeed, given that
about half of the active isavuconazole moiety in humans is excreted as metabolites in
urine (31), that was likely to be a substantial contributor to the radioactivity detected
in kidney and urinary tract tissues. Furthermore, these studies were conducted in
healthy animals, and so it is not clear whether the extent of tissue penetration might
be substantially affected by inﬂammation associated with infection. Nevertheless, given
the efﬁcacy of isavuconazole in the range of tissues from the aforementioned preclin-
ical studies, clinically relevant alterations in tissue penetration due to inﬂammation may
be unlikely.
In conclusion, this study in rats suggests that there is wide distribution of isavu-
conazole into tissues, including into sanctuary sites, such as the brain, and that the
tissue concentrations are sufﬁciently high to provide an antifungal effect. The study
provides the experimental foundation for a further understanding of the broad clinical
utility of isavuconazole.
MATERIALS AND METHODS
Study drugs. The radiolabeled test article, [cyano-14C]isavuconazonium sulfate, was provided by
Sekisui Medical Co., Ltd. The radiolabel was located on the active product of isavuconazonium sulfate
(Fig. 1). The distribution of the unlabeled inactive moiety, BAL8728, was not monitored. Unlabeled
isavuconazonium sulfate (25 mg/kg isavuconazole equivalent in 0.9% NaCl [10 ml/kg]) and voriconazole
(50 mg/kg [10 ml/kg of a voriconazole {Vfend} oral suspension diluted 1/8 with 0.9% NaCl]) were used
for the assessment of isavuconazole and voriconazole concentrations in brain tissue and plasma.
Animals. All animal procedures were performed in an Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC)-accredited facility. The study was conducted in accordance with the
Wisconsin Department of Health Services Radiation Protection Section (license no. 025-1076-01) and the
FDA good laboratory practice (GLP) regulations in 21 CFR 58 (GLP for nonclinical laboratory studies), with
the following exception: the radiolabeled test articles were not characterized in accordance with GLP or
good manufacturing practice (GMP) regulations. Animal procedures and handling at Basilea Pharma-
ceutica International Ltd. complied with the accredited Bundesamt für Veterinärwesen (Basel, Switzer-
land) protocols and licenses. All animal procedures conducted at Covance were in compliance with
Animal Welfare Act regulations (9 CFR 3).
Male Long-Evans rats (body weight range, 231 to 262 g) and male Sprague-Dawley rats (body weight
range, 213 to 242 g) were sourced from Harlan Laboratories, Indianapolis, IN, USA. Male Wistar rats (body
weight range, 297 to 352 g) were sourced from Harlan, The Netherlands. Animals were individually
housed in suspended, stainless steel, wire mesh cages during acclimation and the test period. Environ-
mental controls for the animal room were maintained at a temperature of 20 to 26°C, a relative humidity
of 50%  20%, and a 12-h light/12-h dark cycle. Certiﬁed rodent diet number 2016C (Harlan) was
provided ad libitum, except as speciﬁed in the dosing procedures. Water was provided ad libitum.
QWBA studies of 14C-labeled isavuconazonium sulfate in pigmented rats following single-dose
administration. Ten male Long-Evans rats received [cyano-14C]isavuconazonium sulfate (5 mg/kg) orally
in water. One animal per time point was sacriﬁced for QWBA. Animals under isoﬂurane anesthesia were
sacriﬁced via exsanguination at 1, 2, 4, 8, 24, 72, 144, 336, and 672 h postdose. At termination, blood (2
to 10 ml) was collected in heparinized tubes and stored at 5°C until aliquoted for radioanalysis by LSC.
The rats were immediately frozen solid in CO2–n-hexane for future analysis.
The quantitative distribution of 14C concentrations was assessed by QWBA using radioluminography
(Covance Laboratories Inc., Madison, WI, USA). Forty-micrometer sections were collected on adhesive
tape at six levels of interest in the sagittal plane using a Leica CM 3600 cryomicrotome and dried at
20°C (for a detailed description of cryosectioning for QWBA, see reference 32). All major tissues, organs,
and biological ﬂuids were examined. Gastrointestinal contents were not evaluated. Mounted sections
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were exposed on phosphorimaging screens, with blood standards being spiked with known levels of
radioactivity for subsequent calibration of the image analysis software (for details on the linearity and
variability of the standards, see references 33 and 34). Screens were exposed for 7 days and were scanned
using whole-body autoradiography, and MCID software (Interfocus Imaging Ltd., Cambridge, UK) was
used to quantitate the radioactivity. Autoradiographic standard image data were sampled using Inter-
Focus Imaging Ltd. MCID analysis software to create a calibrated standard curve. Tissue concentrations
were interpolated from each standard curve and converted from nanocuries per gram to microgram
equivalents per gram on the basis of the test article speciﬁc activity (free base) after applying a correction
factor of 1.1352 (sulfate/free form).
QWBA study of 14C-labeled isavuconazonium sulfate in albino rats following repeated dose
administration. Seventeen male Sprague-Dawley rats received [cyano-14C]isavuconazonium sulfate (30
mg/kg/day orally in water; the dose was based on the salt form) for 21 days. Blood samples and bodies
were collected for QWBA. Animals (one animal per time point) were sacriﬁced on day 1 at 1, 4, 8, and 24
h postdose, on days 7 and 14 at 1 h and 24 h postdose, and on day 21 predose (24 h postdose on day
20) and at 1, 4, 8, 24, 72, 168, 336, and 672 h postdose for QWBA. Collection of blood samples at
termination, methods of sacriﬁce, carcass handling, and LSC and QWBA methods were those used in the
single-dose study of the 14C-labeled isavuconazonium sulfate tissue distribution described above.
For both QWBA studies, the limit of quantiﬁcation was 0.02 g eq/g for 14C-labeled isavuconazonium
sulfate in QWBA. Pharmacokinetic parameters (half-life [t1/2], AUCinf, and AUC from time zero to the last
measurable time point [AUClast]) were calculated using WinNonlin software (professional edition, version
5.2; Certara USA, Inc., Princeton, NJ, USA).
Liquid scintillation counting measurement of 14C-labeled isavuconazonium sulfate in blood
and plasma. For measurement of radioactivity in blood and plasma, blood samples (2 to 10 ml) from all
animals used in the single- and repeated-dose experiments were collected in tubes containing sodium
heparin and placed on ice. Duplicate weighed aliquots from each sample were taken to obtain
measurements in plasma (prepared by centrifugation at 1,300  g for 10 min at 5°C) or blood. For blood
samples, PerkinElmer solubilizing agent was added to digest the samples (1 h, 60°C) before addition of
0.1 M disodium EDTA (to reduce foaming) and 30% hydrogen peroxide (to remove the color). Samples
were stored overnight to allow the dissipation of foaming before analysis. Ultima Gold XR scintillation
cocktail was added directly to plasma or digested blood, and the samples were shaken and analyzed
by LSC.
Brain and plasma levels of isavuconazonium, isavuconazole, and voriconazole in rats following
a single oral dose of unlabeled isavuconazonium sulfate or voriconazole. Two groups of 24 male
Wistar rats received a single dose of either isavuconazonium sulfate (25 mg/kg [10 ml/kg] isavuconazole
equivalent in 0.9% NaCl) or voriconazole (50 mg/kg [10 ml/kg of a voriconazole oral suspension diluted
1:8 with 0.9% NaCl]). The doses of isavuconazole and voriconazole were chosen to slightly exceed the
clinically relevant human equivalent doses (approximately 20 mg/kg and 40 mg/kg, respectively). Blood
samples were collected by cardiac puncture from three rats per time point (predose and 15 min, 30 min,
and 1, 2, 3, 6, 8, and 24 h postdose) while the animals were under isoﬂurane anesthesia and placed in
heparinized vials. The plasma proteins were precipitated by addition of a 5-fold excess of acetonitrile
(containing 0.5% triﬂuoroacetic acid) for measurement of isavuconazonium, isavuconazole, and vori-
conazole concentrations using a validated liquid chromatography-tandem mass spectrometry (LC-MS/
MS) method (see below). Immediately after terminal blood collection, the brains were collected, weighed,
frozen in liquid nitrogen, and stored at 80°C until processing for assessment of the concentrations of
isavuconazonium, isavuconazole, and voriconazole by LC-MS/MS. The rat brains were diluted 1:5 with
water and homogenized for 60 s at a high velocity with an Ultra-Turrax tube disperser (IKA Werke GmbH
& Co. KG, Staufen, Germany).
For LC-MS/MS, paraoxon and citric acid were ﬁrst added to samples for analysis of isavuconazonium
sulfate to prevent decomposition (ﬁnal concentrations, 1 mM and 20 mM, respectively). Calibration and
quality control (QC) solutions of isavuconazonium, isavuconazole, and voriconazole were prepared with
150 l of an internal standard solution (10 ng/ml each of isavuconazonium-d4, isavuconazole-d4, and
pyridooxazinone in acetonitrile-triﬂuoroacetate [TFA] at 100:0.05) and 50 l of stock solutions of
isavuconazonium, isavuconazole (in dimethyl sulfoxide [DMSO]), or voriconazole (in acetonitrile-TFA at
100:0.05) to the following ﬁnal ranges of concentrations for calibration and QC: for isavuconazonium, 10
to 500 ng/ml and 25 to 250 ng/ml, respectively; for isavuconazole, 10 to 1,000 ng/ml and 25 to 2,500
ng/ml, respectively; and for voriconazole, 10 to 5,000 ng/ml and 25 to 2,500 ng/ml, respectively.
Unknown rat plasma and brain homogenate samples (50 l) were also mixed with 150 l of the internal
standard solution for analysis. All samples were centrifuged, supernatants were transferred to new tubes
and diluted 10-fold if necessary (with plasma for plasma samples or with water for brain tissue samples),
and 2 l was injected into the LC-MS/MS instrument (Xevo TQ-S; Waters Corporation, Manchester, UK).
The limit of quantiﬁcation for all analytes was 10 ng/ml and 50 ng/g in plasma and brain, respectively.
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